NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commer...
23 Dezembro 2019 - 6:05PM
NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the
company has entered into an exclusive worldwide license agreement
with Ellipses Pharma Limited (Ellipses) for the development of and
rights to commercialize NLG207 (formerly CRLX101), a nanoparticle
formulation of the topoisomerase 1 inhibitor camptothecin. This
license agreement signed by NewLink Genetics and Ellipses is
effective as of December 17, 2019. Under the terms of the
agreement, Ellipses purchased NewLink’s inventory of NLG207 related
materials, and NewLink will have the potential to receive future
royalty payments or a share of any future economics related to
NLG207. As part of the license agreement, Ellipses also
gained the rights to develop and commercialize CRLX-301, a
nanoparticle formulation of docetaxel that has completed a Phase 1a
study.
“We are pleased to announce today this license agreement with
Ellipses for NLG207, a compound which showed encouraging Phase 2
results in refractory ovarian cancer as presented at the
American Association for Cancer Research (AACR) conference in April
2019,” commented Eugene Kennedy, MD, Chief Medical Officer and
member of NewLink’s Office of the CEO. “We are delighted that this
agreement provides a path forward for this promising agent while
allowing NewLink to focus on our core priorities.”
Dr. Rajan Jethwa, Chief Executive Officer and a founder of
Ellipses, commented: “We are excited to have reached an agreement
with NewLink on a worldwide license for NLG207. Our Scientific
Affairs Group confirmed that this compound has shown some
encouraging signs in Phase 2 trials and has the potential to
improve the standard of care for patients with ovarian cancer that
recurs after initial treatment.” Dr Jethwa continued, “Our
dedicated clinical trials team is eager to rapidly progress the
development of this compound for patients suffering from a
devastating disease and who currently have relatively few treatment
options.”
About Ellipses Pharma Limited
Ellipses Pharma is a global drug development company focused
exclusively on the development of innovative cancer medicines and
treatments. Ellipses’ world class management team leverages
the experience and expertise of one of the world’s largest
cancer-focused key opinion leader groups to select, in-license and
fund development of the most promising scientific discoveries. Its
worldwide reach and asset-focused approach transforms the clinical
trials’ process to make the very best drugs and therapies available
to patients with cancer at speed. For more information,
please visit https://ellipses.life/.
About NewLink Genetics Corporation
NewLink Genetics is a clinical-stage biopharmaceutical company
that has historically focused on developing novel immunotherapeutic
products for the treatment of patients with cancer. On September
30, 2019, NewLink announced its intent to merge with Lumos Pharma,
a private clinical-stage biopharmaceutical company targeting rare
and neglected diseases. At the close of the proposed merger, the
combined company will operate as Lumos Pharma focused on Lumos’
sole product candidate, LUM-201 (ibutamoren), an oral growth
hormone (GH) secretagogue targeting pediatric growth hormone
deficiency (PGHD) and other rare endocrine disorders. If approved,
LUM-201 has the potential to represent the first orally
administered growth hormone stimulating therapy for a subset of
PGHD patients, an established market where daily recombinant human
growth hormone injections represent the current standard-of-care
treatment regimen. For more information, please visit
www.NewLinkGenetics.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements of NewLink Genetics that involve substantial
risks and uncertainties. All statements contained in this press
release are forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. The words
“forecast,” “projected,” "guidance," "upcoming," "will," "plan,"
“intend,” "anticipate," "approximate," "expect," “potential,” or
the negative of these terms or other similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements include, among others, statements
regarding future royalty payments, milestones or other economic
interests; and any other statements other than statements of
historical fact. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the
forward-looking statements that NewLink Genetics makes
due to a number of important factors, risks that could cause actual
results to differ materially from those matters expressed in or
implied by such forward-looking statements are discussed in "Risk
Factors" and elsewhere in NewLink Genetics' Quarterly
Report on Form 10-Q for the quarter ended September 30,
2019 and other reports filed with the SEC. The
forward-looking statements in this press release
represent NewLink Genetics’ views as of the date of this
press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink
Genetics' views as of any date subsequent to the date of this
press release.
Investor & Media Contact:
Lisa MillerDirector of Investor RelationsNewLink
Genetics515-598-2555lmiller@linkp.com
Source: NewLink Genetics Corporation
NewLink Genetics (NASDAQ:NLNK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
NewLink Genetics (NASDAQ:NLNK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024